Core Session 3: Immunotherapy

Chair(s)

• 

  Nikhil Munshi, MD

  Kraft Family Chair, Director of Basic and Correlative Science, Professor of Medicine, Harvard Medical School
  Dana-Farber Cancer Institute, Harvard Medical School
  Boston, Massachusetts

Co-Chair(s)

• 

  Kenneth Anderson, MD

  Professor of Medicine
  Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  Boston, Massachusetts

Presentations:

• 09:00 - 09:10 East Coast USA Time

  Role of target/tumor as mechanism of resistance to CAR T-cell redirecting therapies
  

  Speaker: Paola Neri, MD, PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary
• 09:10 - 09:20 East Coast USA Time

  Role of immune system as mechanism of resistance to T-cell engagers
  

  Speaker: Samir Parekh, MD (he/him/his) – Mount Sinai Medical Center, New York, NY, USA
• 09:20 - 09:30 East Coast USA Time

  Optimal dose, schedule, and timing
  

  Speaker: Surbhi Sidana, MD – Stanford University School of Medicine
• 09:30 - 09:40 East Coast USA Time

  Toxicity management, infection management, secondary cancers and delayed neurotoxicity
  

  Speaker: Benjamin Puliafito, MD – Massachusetts General Hospital
• 09:40 - 09:55 East Coast USA Time

  Future Directions and Challenges
  

  Speaker: Niels W.C.J. van de Donk, MD, PhD (he/him/his) – Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
• 09:55 - 10:20 East Coast USA Time

  Round Table discussion
  

  Panelist: Adam D. Cohen, MD – Perelman School of Medicine, University of Pennsylvania

  Panelist: Hermann Einsele, MD, FRCP (he/him/his) – Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany

  Panelist: Morie A. Gertz, MD – Mayo Clinic Rochester

  Panelist: Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD – NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK